APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biosimilars

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Biosimilars Market Analysis and Forecast 2026-2032

22 December 2025210 pages

Choose your research edition.

Industry ResearchBiosimilars Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Biosimilars Industry Growth and Trends Forecast to 2032127 pages · $3,450 USDMarket StructureGlobal Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biosimilars Market Outlook and Growth Opportunities 2026212 pages · $4,250 USDMarket Analysis & ForecastGlobal Biosimilars Market Analysis and Forecast 2026-2032210 pages · $4,950 USD

Market perspective

The global Biosimilars market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Biosimilars include Teva Pharmaceutical, Samsung Biologics, Novartis, Merck KgaA, Mylan, Roche, Eli Lilly, Pfizer and Gan & Lee Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Biosimilars, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Biosimilars, also provides the sales of main regions and countries. Of the upcoming market potential for Biosimilars, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Biosimilars sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Biosimilars market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Biosimilars sales, projected growth trends, production technology, application and end-user industry.

Biosimilars Segment by Company

Teva Pharmaceutical

Samsung Biologics

Novartis

Merck KgaA

Mylan

Roche

Eli Lilly

Pfizer

Gan & Lee Pharmaceuticals

Biogen

Amgen

Stada Arzneimittel AG

Probiomed

JCR Pharmaceuticals

Gedeon Richter

Fresenius Kabi AG

Dr. Reddy's Laboratories

Coherus Bioscience

Chong Kun Dang

Celltrion

Boehringer Ingelheim

Biocon

Biocad

Apotex

Biosimilars Segment by Type

Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)

Recombinant Glycosylated Proteins

Biosimilars Segment by Application

Oncology

Blood Disorders

Growth Hormonal Deficiency

Chronic and Autoimmune Disorders

Others

Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Biosimilars in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Biosimilars manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biosimilars sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Biosimilars Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon) Major Manufacturers Table 3. Recombinant Glycosylated Proteins Major Manufacturers Table 4. Global Biosimilars Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Oncology Major Manufacturers Table 6. Blood Disorders Major Manufacturers Table 7. Growth Hormonal Deficiency Major Manufacturers Table 8. Chronic and Autoimmune Disorders Major Manufacturers Table 9. Others Major Manufacturers Table 10. Biosimilars Industry Trends Table 11. Biosimilars Industry Drivers Table 12. Biosimilars Industry Opportunities and Challenges Table 13. Biosimilars Industry Restraints Table 14. Global Biosimilars Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Biosimilars Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Biosimilars Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Biosimilars Revenue Market Share by Region (2021-2026) Table 18. Global Biosimilars Revenue Market Share by Region (2027-2032) Table 19. Global Biosimilars Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 20. Global Biosimilars Sales by Region (2021-2026) & (k units) Table 21. Global Biosimilars Sales by Region (2027-2032) & (k units) Table 22. Global Biosimilars Sales Market Share by Region (2021-2026) Table 23. Global Biosimilars Sales Market Share by Region (2027-2032) Table 24. Global Biosimilars Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Biosimilars Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Biosimilars Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Biosimilars Sales Market Share by Manufacturers (2021-2026) Table 28. Global Biosimilars Sales Price (US$/unit) of Manufacturers (2021-2026) Table 29. Global Biosimilars Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Biosimilars Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Biosimilars Manufacturers, Product Type & Application Table 32. Global Biosimilars Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Biosimilars by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Biosimilars Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Biosimilars Revenue Market Share by Type (2021-2026) Table 39. Global Biosimilars Revenue Market Share by Type (2027-2032) Table 40. Global Biosimilars Sales by Type 2021 VS 2025 VS 2032 (k units) Table 41. Global Biosimilars Sales by Type (2021-2026) & (k units) Table 42. Global Biosimilars Sales by Type (2027-2032) & (k units) Table 43. Global Biosimilars Sales Market Share by Type (2021-2026) Table 44. Global Biosimilars Sales Market Share by Type (2027-2032) Table 45. Global Biosimilars Price by Type (2021-2026) & (US$/unit) Table 46. Global Biosimilars Price by Type (2027-2032) & (US$/unit) Table 47. Global Biosimilars Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Biosimilars Revenue Market Share by Application (2021-2026) Table 51. Global Biosimilars Revenue Market Share by Application (2027-2032) Table 52. Global Biosimilars Sales by Application 2021 VS 2025 VS 2032 (k units) Table 53. Global Biosimilars Sales by Application (2021-2026) & (k units) Table 54. Global Biosimilars Sales by Application (2027-2032) & (k units) Table 55. Global Biosimilars Sales Market Share by Application (2021-2026) Table 56. Global Biosimilars Sales Market Share by Application (2027-2032) Table 57. Global Biosimilars Price by Application (2021-2026) & (US$/unit) Table 58. Global Biosimilars Price by Application (2027-2032) & (US$/unit) Table 59. Teva Pharmaceutical Company Information Table 60. Teva Pharmaceutical Business Overview Table 61. Teva Pharmaceutical Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 62. Teva Pharmaceutical Biosimilars Product Portfolio Table 63. Teva Pharmaceutical Recent Development Table 64. Samsung Biologics Company Information Table 65. Samsung Biologics Business Overview Table 66. Samsung Biologics Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Samsung Biologics Biosimilars Product Portfolio Table 68. Samsung Biologics Recent Development Table 69. Novartis Company Information Table 70. Novartis Business Overview Table 71. Novartis Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Novartis Biosimilars Product Portfolio Table 73. Novartis Recent Development Table 74. Merck KgaA Company Information Table 75. Merck KgaA Business Overview Table 76. Merck KgaA Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Merck KgaA Biosimilars Product Portfolio Table 78. Merck KgaA Recent Development Table 79. Mylan Company Information Table 80. Mylan Business Overview Table 81. Mylan Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Mylan Biosimilars Product Portfolio Table 83. Mylan Recent Development Table 84. Roche Company Information Table 85. Roche Business Overview Table 86. Roche Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Roche Biosimilars Product Portfolio Table 88. Roche Recent Development Table 89. Eli Lilly Company Information Table 90. Eli Lilly Business Overview Table 91. Eli Lilly Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Eli Lilly Biosimilars Product Portfolio Table 93. Eli Lilly Recent Development Table 94. Pfizer Company Information Table 95. Pfizer Business Overview Table 96. Pfizer Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Pfizer Biosimilars Product Portfolio Table 98. Pfizer Recent Development Table 99. Gan & Lee Pharmaceuticals Company Information Table 100. Gan & Lee Pharmaceuticals Business Overview Table 101. Gan & Lee Pharmaceuticals Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Gan & Lee Pharmaceuticals Biosimilars Product Portfolio Table 103. Gan & Lee Pharmaceuticals Recent Development Table 104. Biogen Company Information Table 105. Biogen Business Overview Table 106. Biogen Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Biogen Biosimilars Product Portfolio Table 108. Biogen Recent Development Table 109. Amgen Company Information Table 110. Amgen Business Overview Table 111. Amgen Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Amgen Biosimilars Product Portfolio Table 113. Amgen Recent Development Table 114. Stada Arzneimittel AG Company Information Table 115. Stada Arzneimittel AG Business Overview Table 116. Stada Arzneimittel AG Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Stada Arzneimittel AG Biosimilars Product Portfolio Table 118. Stada Arzneimittel AG Recent Development Table 119. Probiomed Company Information Table 120. Probiomed Business Overview Table 121. Probiomed Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Probiomed Biosimilars Product Portfolio Table 123. Probiomed Recent Development Table 124. JCR Pharmaceuticals Company Information Table 125. JCR Pharmaceuticals Business Overview Table 126. JCR Pharmaceuticals Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. JCR Pharmaceuticals Biosimilars Product Portfolio Table 128. JCR Pharmaceuticals Recent Development Table 129. Gedeon Richter Company Information Table 130. Gedeon Richter Business Overview Table 131. Gedeon Richter Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. Gedeon Richter Biosimilars Product Portfolio Table 133. Gedeon Richter Recent Development Table 134. Fresenius Kabi AG Company Information Table 135. Fresenius Kabi AG Business Overview Table 136. Fresenius Kabi AG Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 137. Fresenius Kabi AG Biosimilars Product Portfolio Table 138. Fresenius Kabi AG Recent Development Table 139. Dr. Reddy's Laboratories Company Information Table 140. Dr. Reddy's Laboratories Business Overview Table 141. Dr. Reddy's Laboratories Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 142. Dr. Reddy's Laboratories Biosimilars Product Portfolio Table 143. Dr. Reddy's Laboratories Recent Development Table 144. Coherus Bioscience Company Information Table 145. Coherus Bioscience Business Overview Table 146. Coherus Bioscience Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 147. Coherus Bioscience Biosimilars Product Portfolio Table 148. Coherus Bioscience Recent Development Table 149. Chong Kun Dang Company Information Table 150. Chong Kun Dang Business Overview Table 151. Chong Kun Dang Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 152. Chong Kun Dang Biosimilars Product Portfolio Table 153. Chong Kun Dang Recent Development Table 154. Celltrion Company Information Table 155. Celltrion Business Overview Table 156. Celltrion Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 157. Celltrion Biosimilars Product Portfolio Table 158. Celltrion Recent Development Table 159. Boehringer Ingelheim Company Information Table 160. Boehringer Ingelheim Business Overview Table 161. Boehringer Ingelheim Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 162. Boehringer Ingelheim Biosimilars Product Portfolio Table 163. Boehringer Ingelheim Recent Development Table 164. Biocon Company Information Table 165. Biocon Business Overview Table 166. Biocon Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 167. Biocon Biosimilars Product Portfolio Table 168. Biocon Recent Development Table 169. Biocad Company Information Table 170. Biocad Business Overview Table 171. Biocad Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 172. Biocad Biosimilars Product Portfolio Table 173. Biocad Recent Development Table 174. Apotex Company Information Table 175. Apotex Business Overview Table 176. Apotex Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 177. Apotex Biosimilars Product Portfolio Table 178. Apotex Recent Development Table 179. North America Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 180. North America Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 181. North America Biosimilars Sales by Type (2021-2026) & (k units) Table 182. North America Biosimilars Sales by Type (2027-2032) & (k units) Table 183. North America Biosimilars Sales Price by Type (2021-2026) & (US$/unit) Table 184. North America Biosimilars Sales Price by Type (2027-2032) & (US$/unit) Table 185. North America Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 186. North America Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 187. North America Biosimilars Sales by Application (2021-2026) & (k units) Table 188. North America Biosimilars Sales by Application (2027-2032) & (k units) Table 189. North America Biosimilars Sales Price by Application (2021-2026) & (US$/unit) Table 190. North America Biosimilars Sales Price by Application (2027-2032) & (US$/unit) Table 191. North America Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 192. North America Biosimilars Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 193. North America Biosimilars Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 194. North America Biosimilars Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 195. North America Biosimilars Sales by Country (2021-2026) & (k units) Table 196. North America Biosimilars Sales by Country (2027-2032) & (k units) Table 197. North America Biosimilars Sales Price by Country (2021-2026) & (US$/unit) Table 198. North America Biosimilars Sales Price by Country (2027-2032) & (US$/unit) Table 199. United States Biosimilars Revenue (2021-2032) & (US$ Million) Table 200. Canada Biosimilars Revenue (2021-2032) & (US$ Million) Table 201. Mexico Biosimilars Revenue (2021-2032) & (US$ Million) Table 202. Europe Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 203. Europe Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 204. Europe Biosimilars Sales by Type (2021-2026) & (k units) Table 205. Europe Biosimilars Sales by Type (2027-2032) & (k units) Table 206. Europe Biosimilars Sales Price by Type (2021-2026) & (US$/unit) Table 207. Europe Biosimilars Sales Price by Type (2027-2032) & (US$/unit) Table 208. Europe Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 209. Europe Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 210. Europe Biosimilars Sales by Application (2021-2026) & (k units) Table 211. Europe Biosimilars Sales by Application (2027-2032) & (k units) Table 212. Europe Biosimilars Sales Price by Application (2021-2026) & (US$/unit) Table 213. Europe Biosimilars Sales Price by Application (2027-2032) & (US$/unit) Table 214. Europe Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 215. Europe Biosimilars Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 216. Europe Biosimilars Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 217. Europe Biosimilars Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 218. Europe Biosimilars Sales by Country (2021-2026) & (k units) Table 219. Europe Biosimilars Sales by Country (2027-2032) & (k units) Table 220. Europe Biosimilars Sales Price by Country (2021-2026) & (US$/unit) Table 221. Europe Biosimilars Sales Price by Country (2027-2032) & (US$/unit) Table 222. Germany Biosimilars Revenue (2021-2032) & (US$ Million) Table 223. France Biosimilars Revenue (2021-2032) & (US$ Million) Table 224. U.K. Biosimilars Revenue (2021-2032) & (US$ Million) Table 225. Italy Biosimilars Revenue (2021-2032) & (US$ Million) Table 226. Russia Biosimilars Revenue (2021-2032) & (US$ Million) Table 227. Spain Biosimilars Revenue (2021-2032) & (US$ Million) Table 228. Netherlands Biosimilars Revenue (2021-2032) & (US$ Million) Table 229. Switzerland Biosimilars Revenue (2021-2032) & (US$ Million) Table 230. Sweden Biosimilars Revenue (2021-2032) & (US$ Million) Table 231. Poland Biosimilars Revenue (2021-2032) & (US$ Million) Table 232. China Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 233. China Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 234. China Biosimilars Sales by Type (2021-2026) & (k units) Table 235. China Biosimilars Sales by Type (2027-2032) & (k units) Table 236. China Biosimilars Sales Price by Type (2021-2026) & (US$/unit) Table 237. China Biosimilars Sales Price by Type (2027-2032) & (US$/unit) Table 238. China Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 239. China Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 240. China Biosimilars Sales by Application (2021-2026) & (k units) Table 241. China Biosimilars Sales by Application (2027-2032) & (k units) Table 242. China Biosimilars Sales Price by Application (2021-2026) & (US$/unit) Table 243. China Biosimilars Sales Price by Application (2027-2032) & (US$/unit) Table 244. Asia Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 245. Asia Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 246. Asia Biosimilars Sales by Type (2021-2026) & (k units) Table 247. Asia Biosimilars Sales by Type (2027-2032) & (k units) Table 248. Asia Biosimilars Sales Price by Type (2021-2026) & (US$/unit) Table 249. Asia Biosimilars Sales Price by Type (2027-2032) & (US$/unit) Table 250. Asia Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 251. Asia Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 252. Asia Biosimilars Sales by Application (2021-2026) & (k units) Table 253. Asia Biosimilars Sales by Application (2027-2032) & (k units) Table 254. Asia Biosimilars Sales Price by Application (2021-2026) & (US$/unit) Table 255. Asia Biosimilars Sales Price by Application (2027-2032) & (US$/unit) Table 256. Asia Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 257. Asia Biosimilars Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 258. Asia Biosimilars Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 259. Asia Biosimilars Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 260. Asia Biosimilars Sales by Country (2021-2026) & (k units) Table 261. Asia Biosimilars Sales by Country (2027-2032) & (k units) Table 262. Asia Biosimilars Sales Price by Country (2021-2026) & (US$/unit) Table 263. Asia Biosimilars Sales Price by Country (2027-2032) & (US$/unit) Table 264. Japan Biosimilars Revenue (2021-2032) & (US$ Million) Table 265. South Korea Biosimilars Revenue (2021-2032) & (US$ Million) Table 266. India Biosimilars Revenue (2021-2032) & (US$ Million) Table 267. Australia Biosimilars Revenue (2021-2032) & (US$ Million) Table 268. Taiwan Biosimilars Revenue (2021-2032) & (US$ Million) Table 269. Southeast Asia Biosimilars Revenue (2021-2032) & (US$ Million) Table 270. SAMEA Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 271. SAMEA Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 272. SAMEA Biosimilars Sales by Type (2021-2026) & (k units) Table 273. SAMEA Biosimilars Sales by Type (2027-2032) & (k units) Table 274. SAMEA Biosimilars Sales Price by Type (2021-2026) & (US$/unit) Table 275. SAMEA Biosimilars Sales Price by Type (2027-2032) & (US$/unit) Table 276. SAMEA Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 277. SAMEA Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 278. SAMEA Biosimilars Sales by Application (2021-2026) & (k units) Table 279. SAMEA Biosimilars Sales by Application (2027-2032) & (k units) Table 280. SAMEA Biosimilars Sales Price by Application (2021-2026) & (US$/unit) Table 281. SAMEA Biosimilars Sales Price by Application (2027-2032) & (US$/unit) Table 282. SAMEA Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 283. SAMEA Biosimilars Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 284. SAMEA Biosimilars Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 285. SAMEA Biosimilars Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 286. SAMEA Biosimilars Sales by Country (2021-2026) & (k units) Table 287. SAMEA Biosimilars Sales by Country (2027-2032) & (k units) Table 288. SAMEA Biosimilars Sales Price by Country (2021-2026) & (US$/unit) Table 289. SAMEA Biosimilars Sales Price by Country (2027-2032) & (US$/unit) Table 290. Brazil Biosimilars Revenue (2021-2032) & (US$ Million) Table 291. Argentina Biosimilars Revenue (2021-2032) & (US$ Million) Table 292. Chile Biosimilars Revenue (2021-2032) & (US$ Million) Table 293. Colombia Biosimilars Revenue (2021-2032) & (US$ Million) Table 294. Peru Biosimilars Revenue (2021-2032) & (US$ Million) Table 295. Saudi Arabia Biosimilars Revenue (2021-2032) & (US$ Million) Table 296. Israel Biosimilars Revenue (2021-2032) & (US$ Million) Table 297. UAE Biosimilars Revenue (2021-2032) & (US$ Million) Table 298. Turkey Biosimilars Revenue (2021-2032) & (US$ Million) Table 299. Iran Biosimilars Revenue (2021-2032) & (US$ Million) Table 300. Egypt Biosimilars Revenue (2021-2032) & (US$ Million) Table 301. Key Raw Materials Table 302. Raw Materials Key Suppliers Table 303. Biosimilars Distributors List Table 304. Biosimilars Customers List Table 305. Research Programs/Design for This Report Table 306. Authors List of This Report Table 307. Secondary Sources Table 308. Primary Sources List of Figures Figure 1. Biosimilars Image Figure 2. Global Biosimilars Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biosimilars Market Size Share 2021 VS 2025 VS 2032 Figure 4. Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon) Image Figure 5. Recombinant Glycosylated Proteins Image Figure 6. Global Biosimilars Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Biosimilars Market Size Share 2021 VS 2025 VS 2032 Figure 8. Oncology Image Figure 9. Blood Disorders Image Figure 10. Growth Hormonal Deficiency Image Figure 11. Chronic and Autoimmune Disorders Image Figure 12. Others Image Figure 13. Global Biosimilars Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Biosimilars Revenue (2021-2032) & (US$ Million) Figure 15. Global Biosimilars Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Biosimilars Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Biosimilars Revenue Market Share by Region (2021-2032) Figure 18. Global Biosimilars Sales (2021-2032) & (k units) Figure 19. Global Biosimilars Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 20. Global Biosimilars Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Biosimilars Sales YoY (2021-2032) & (k units) Figure 22. Europe Biosimilars Sales YoY (2021-2032) & (k units) Figure 23. China Biosimilars Sales YoY (2021-2032) & (k units) Figure 24. Asia (Excluding China) Biosimilars Sales YoY (2021-2032) & (k units) Figure 25. South America, Middle East and Africa Biosimilars Sales YoY (2021-2032) & (k units) Figure 26. Global Biosimilars Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Biosimilars Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Biosimilars Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Biosimilars Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Biosimilars Revenue Market Share by Type (2021-2032) Figure 32. Global Biosimilars Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 33. Global Biosimilars Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Biosimilars Sales Market Share by Type (2021-2032) Figure 35. Global Biosimilars Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Biosimilars Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Biosimilars Revenue Market Share by Application (2021-2032) Figure 38. Global Biosimilars Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 39. Global Biosimilars Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Biosimilars Sales Market Share by Application (2021-2032) Figure 41. North America Biosimilars Revenue Share by Type (2021-2032) Figure 42. North America Biosimilars Sales Share by Type (2021-2032) Figure 43. North America Biosimilars Revenue Share by Application (2021-2032) Figure 44. North America Biosimilars Sales Share by Application (2021-2032) Figure 45. North America Biosimilars Revenue Share by Country (2021-2032) Figure 46. North America Biosimilars Sales Share by Country (2021-2032) Figure 47. Europe Biosimilars Revenue Share by Type (2021-2032) Figure 48. Europe Biosimilars Sales Share by Type (2021-2032) Figure 49. Europe Biosimilars Revenue Share by Application (2021-2032) Figure 50. Europe Biosimilars Sales Share by Application (2021-2032) Figure 51. Europe Biosimilars Revenue Share by Country (2021-2032) Figure 52. Europe Biosimilars Sales Share by Country (2021-2032) Figure 53. China Biosimilars Revenue Share by Type (2021-2032) Figure 54. China Biosimilars Sales Share by Type (2021-2032) Figure 55. China Biosimilars Revenue Share by Application (2021-2032) Figure 56. China Biosimilars Sales Share by Application (2021-2032) Figure 57. Asia Biosimilars Revenue Share by Type (2021-2032) Figure 58. Asia Biosimilars Sales Share by Type (2021-2032) Figure 59. Asia Biosimilars Revenue Share by Application (2021-2032) Figure 60. Asia Biosimilars Sales Share by Application (2021-2032) Figure 61. Asia Biosimilars Revenue Share by Country (2021-2032) Figure 62. Asia Biosimilars Sales Share by Country (2021-2032) Figure 63. SAMEA Biosimilars Revenue Share by Type (2021-2032) Figure 64. SAMEA Biosimilars Sales Share by Type (2021-2032) Figure 65. SAMEA Biosimilars Revenue Share by Application (2021-2032) Figure 66. SAMEA Biosimilars Sales Share by Application (2021-2032) Figure 67. SAMEA Biosimilars Revenue Share by Country (2021-2032) Figure 68. SAMEA Biosimilars Sales Share by Country (2021-2032) Figure 69. Biosimilars Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Biosimilars Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
  • Recombinant Glycosylated Proteins
Applications
  • Oncology
  • Blood Disorders
  • Growth Hormonal Deficiency
  • Chronic and Autoimmune Disorders
  • Others
Companies covered
  • Teva Pharmaceutical
  • Samsung Biologics
  • Novartis
  • Merck KgaA
  • Mylan
  • Roche
  • Eli Lilly
  • Pfizer
  • Gan & Lee Pharmaceuticals
  • Biogen
  • Amgen
  • Stada Arzneimittel AG
  • Probiomed
  • JCR Pharmaceuticals
  • Gedeon Richter
  • Fresenius Kabi AG
  • Dr. Reddy's Laboratories
  • Coherus Bioscience
  • Chong Kun Dang
  • Celltrion
  • Boehringer Ingelheim
  • Biocon
  • Biocad
  • Apotex

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Biosimilars Market by Type
  3. 1.2.1 Global Biosimilars Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
  5. 1.2.3 Recombinant Glycosylated Proteins
  6. 1.3 Biosimilars Market by Application
  7. 1.3.1 Global Biosimilars Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Oncology
  9. 1.3.3 Blood Disorders
  10. 1.3.4 Growth Hormonal Deficiency
  11. 1.3.5 Chronic and Autoimmune Disorders
  12. 1.3.6 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Biosimilars Market Dynamics
  1. 2.1 Biosimilars Industry Trends
  2. 2.2 Biosimilars Industry Drivers
  3. 2.3 Biosimilars Industry Opportunities and Challenges
  4. 2.4 Biosimilars Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Biosimilars Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Biosimilars Revenue by Region
  3. 3.2.1 Global Biosimilars Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Biosimilars Revenue by Region (2021-2026)
  5. 3.2.3 Global Biosimilars Revenue by Region (2027-2032)
  6. 3.2.4 Global Biosimilars Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Biosimilars Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Biosimilars Sales by Region
  9. 3.4.1 Global Biosimilars Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Biosimilars Sales by Region (2021-2026)
  11. 3.4.3 Global Biosimilars Sales by Region (2027-2032)
  12. 3.4.4 Global Biosimilars Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Biosimilars Revenue by Manufacturers
  2. 4.1.1 Global Biosimilars Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Biosimilars Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Biosimilars Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Biosimilars Sales by Manufacturers
  6. 4.2.1 Global Biosimilars Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Biosimilars Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Biosimilars Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Biosimilars Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Biosimilars Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Biosimilars Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Biosimilars Manufacturers, Product Type & Application
  13. 4.7 Global Biosimilars Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Biosimilars Market CR5 and HHI
  16. 4.8.2 2025 Biosimilars Tier 1, Tier 2, and Tier 3
5 Biosimilars Market by Type
  1. 5.1 Global Biosimilars Revenue by Type
  2. 5.1.1 Global Biosimilars Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Biosimilars Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Biosimilars Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Biosimilars Sales by Type
  6. 5.2.1 Global Biosimilars Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Biosimilars Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Biosimilars Sales Market Share by Type (2021-2032)
  9. 5.3 Global Biosimilars Price by Type
6 Biosimilars Market by Application
  1. 6.1 Global Biosimilars Revenue by Application
  2. 6.1.1 Global Biosimilars Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Biosimilars Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Biosimilars Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Biosimilars Sales by Application
  6. 6.2.1 Global Biosimilars Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Biosimilars Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Biosimilars Sales Market Share by Application (2021-2032)
  9. 6.3 Global Biosimilars Price by Application
7 Company Profiles
  1. 7.1 Teva Pharmaceutical
  2. 7.1.1 Teva Pharmaceutical Company Information
  3. 7.1.2 Teva Pharmaceutical Business Overview
  4. 7.1.3 Teva Pharmaceutical Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Teva Pharmaceutical Biosimilars Product Portfolio
  6. 7.1.5 Teva Pharmaceutical Recent Developments
  7. 7.2 Samsung Biologics
  8. 7.2.1 Samsung Biologics Company Information
  9. 7.2.2 Samsung Biologics Business Overview
  10. 7.2.3 Samsung Biologics Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Samsung Biologics Biosimilars Product Portfolio
  12. 7.2.5 Samsung Biologics Recent Developments
  13. 7.3 Novartis
  14. 7.3.1 Novartis Company Information
  15. 7.3.2 Novartis Business Overview
  16. 7.3.3 Novartis Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Novartis Biosimilars Product Portfolio
  18. 7.3.5 Novartis Recent Developments
  19. 7.4 Merck KgaA
  20. 7.4.1 Merck KgaA Company Information
  21. 7.4.2 Merck KgaA Business Overview
  22. 7.4.3 Merck KgaA Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Merck KgaA Biosimilars Product Portfolio
  24. 7.4.5 Merck KgaA Recent Developments
  25. 7.5 Mylan
  26. 7.5.1 Mylan Company Information
  27. 7.5.2 Mylan Business Overview
  28. 7.5.3 Mylan Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Mylan Biosimilars Product Portfolio
  30. 7.5.5 Mylan Recent Developments
  31. 7.6 Roche
  32. 7.6.1 Roche Company Information
  33. 7.6.2 Roche Business Overview
  34. 7.6.3 Roche Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Roche Biosimilars Product Portfolio
  36. 7.6.5 Roche Recent Developments
  37. 7.7 Eli Lilly
  38. 7.7.1 Eli Lilly Company Information
  39. 7.7.2 Eli Lilly Business Overview
  40. 7.7.3 Eli Lilly Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Eli Lilly Biosimilars Product Portfolio
  42. 7.7.5 Eli Lilly Recent Developments
  43. 7.8 Pfizer
  44. 7.8.1 Pfizer Company Information
  45. 7.8.2 Pfizer Business Overview
  46. 7.8.3 Pfizer Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Pfizer Biosimilars Product Portfolio
  48. 7.8.5 Pfizer Recent Developments
  49. 7.9 Gan & Lee Pharmaceuticals
  50. 7.9.1 Gan & Lee Pharmaceuticals Company Information
  51. 7.9.2 Gan & Lee Pharmaceuticals Business Overview
  52. 7.9.3 Gan & Lee Pharmaceuticals Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Gan & Lee Pharmaceuticals Biosimilars Product Portfolio
  54. 7.9.5 Gan & Lee Pharmaceuticals Recent Developments
  55. 7.10 Biogen
  56. 7.10.1 Biogen Company Information
  57. 7.10.2 Biogen Business Overview
  58. 7.10.3 Biogen Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Biogen Biosimilars Product Portfolio
  60. 7.10.5 Biogen Recent Developments
  61. 7.11 Amgen
  62. 7.11.1 Amgen Company Information
  63. 7.11.2 Amgen Business Overview
  64. 7.11.3 Amgen Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Amgen Biosimilars Product Portfolio
  66. 7.11.5 Amgen Recent Developments
  67. 7.12 Stada Arzneimittel AG
  68. 7.12.1 Stada Arzneimittel AG Company Information
  69. 7.12.2 Stada Arzneimittel AG Business Overview
  70. 7.12.3 Stada Arzneimittel AG Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Stada Arzneimittel AG Biosimilars Product Portfolio
  72. 7.12.5 Stada Arzneimittel AG Recent Developments
  73. 7.13 Probiomed
  74. 7.13.1 Probiomed Company Information
  75. 7.13.2 Probiomed Business Overview
  76. 7.13.3 Probiomed Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Probiomed Biosimilars Product Portfolio
  78. 7.13.5 Probiomed Recent Developments
  79. 7.14 JCR Pharmaceuticals
  80. 7.14.1 JCR Pharmaceuticals Company Information
  81. 7.14.2 JCR Pharmaceuticals Business Overview
  82. 7.14.3 JCR Pharmaceuticals Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 JCR Pharmaceuticals Biosimilars Product Portfolio
  84. 7.14.5 JCR Pharmaceuticals Recent Developments
  85. 7.15 Gedeon Richter
  86. 7.15.1 Gedeon Richter Company Information
  87. 7.15.2 Gedeon Richter Business Overview
  88. 7.15.3 Gedeon Richter Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Gedeon Richter Biosimilars Product Portfolio
  90. 7.15.5 Gedeon Richter Recent Developments
  91. 7.16 Fresenius Kabi AG
  92. 7.16.1 Fresenius Kabi AG Company Information
  93. 7.16.2 Fresenius Kabi AG Business Overview
  94. 7.16.3 Fresenius Kabi AG Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Fresenius Kabi AG Biosimilars Product Portfolio
  96. 7.16.5 Fresenius Kabi AG Recent Developments
  97. 7.17 Dr. Reddy's Laboratories
  98. 7.17.1 Dr. Reddy's Laboratories Company Information
  99. 7.17.2 Dr. Reddy's Laboratories Business Overview
  100. 7.17.3 Dr. Reddy's Laboratories Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Dr. Reddy's Laboratories Biosimilars Product Portfolio
  102. 7.17.5 Dr. Reddy's Laboratories Recent Developments
  103. 7.18 Coherus Bioscience
  104. 7.18.1 Coherus Bioscience Company Information
  105. 7.18.2 Coherus Bioscience Business Overview
  106. 7.18.3 Coherus Bioscience Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Coherus Bioscience Biosimilars Product Portfolio
  108. 7.18.5 Coherus Bioscience Recent Developments
  109. 7.19 Chong Kun Dang
  110. 7.19.1 Chong Kun Dang Company Information
  111. 7.19.2 Chong Kun Dang Business Overview
  112. 7.19.3 Chong Kun Dang Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Chong Kun Dang Biosimilars Product Portfolio
  114. 7.19.5 Chong Kun Dang Recent Developments
  115. 7.20 Celltrion
  116. 7.20.1 Celltrion Company Information
  117. 7.20.2 Celltrion Business Overview
  118. 7.20.3 Celltrion Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Celltrion Biosimilars Product Portfolio
  120. 7.20.5 Celltrion Recent Developments
  121. 7.21 Boehringer Ingelheim
  122. 7.21.1 Boehringer Ingelheim Company Information
  123. 7.21.2 Boehringer Ingelheim Business Overview
  124. 7.21.3 Boehringer Ingelheim Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  125. 7.21.4 Boehringer Ingelheim Biosimilars Product Portfolio
  126. 7.21.5 Boehringer Ingelheim Recent Developments
  127. 7.22 Biocon
  128. 7.22.1 Biocon Company Information
  129. 7.22.2 Biocon Business Overview
  130. 7.22.3 Biocon Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  131. 7.22.4 Biocon Biosimilars Product Portfolio
  132. 7.22.5 Biocon Recent Developments
  133. 7.23 Biocad
  134. 7.23.1 Biocad Company Information
  135. 7.23.2 Biocad Business Overview
  136. 7.23.3 Biocad Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  137. 7.23.4 Biocad Biosimilars Product Portfolio
  138. 7.23.5 Biocad Recent Developments
  139. 7.24 Apotex
  140. 7.24.1 Apotex Company Information
  141. 7.24.2 Apotex Business Overview
  142. 7.24.3 Apotex Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  143. 7.24.4 Apotex Biosimilars Product Portfolio
  144. 7.24.5 Apotex Recent Developments
8 North America
  1. 8.1 North America Biosimilars Market Size by Type
  2. 8.1.1 North America Biosimilars Revenue by Type (2021-2032)
  3. 8.1.2 North America Biosimilars Sales by Type (2021-2032)
  4. 8.1.3 North America Biosimilars Price by Type (2021-2032)
  5. 8.2 North America Biosimilars Market Size by Application
  6. 8.2.1 North America Biosimilars Revenue by Application (2021-2032)
  7. 8.2.2 North America Biosimilars Sales by Application (2021-2032)
  8. 8.2.3 North America Biosimilars Price by Application (2021-2032)
  9. 8.3 North America Biosimilars Market Size by Country
  10. 8.3.1 North America Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Biosimilars Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Biosimilars Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Biosimilars Market Size by Type
  2. 9.1.1 Europe Biosimilars Revenue by Type (2021-2032)
  3. 9.1.2 Europe Biosimilars Sales by Type (2021-2032)
  4. 9.1.3 Europe Biosimilars Price by Type (2021-2032)
  5. 9.2 Europe Biosimilars Market Size by Application
  6. 9.2.1 Europe Biosimilars Revenue by Application (2021-2032)
  7. 9.2.2 Europe Biosimilars Sales by Application (2021-2032)
  8. 9.2.3 Europe Biosimilars Price by Application (2021-2032)
  9. 9.3 Europe Biosimilars Market Size by Country
  10. 9.3.1 Europe Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Biosimilars Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Biosimilars Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Biosimilars Market Size by Type
  2. 10.1.1 China Biosimilars Revenue by Type (2021-2032)
  3. 10.1.2 China Biosimilars Sales by Type (2021-2032)
  4. 10.1.3 China Biosimilars Price by Type (2021-2032)
  5. 10.2 China Biosimilars Market Size by Application
  6. 10.2.1 China Biosimilars Revenue by Application (2021-2032)
  7. 10.2.2 China Biosimilars Sales by Application (2021-2032)
  8. 10.2.3 China Biosimilars Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Biosimilars Market Size by Type
  2. 11.1.1 Asia Biosimilars Revenue by Type (2021-2032)
  3. 11.1.2 Asia Biosimilars Sales by Type (2021-2032)
  4. 11.1.3 Asia Biosimilars Price by Type (2021-2032)
  5. 11.2 Asia Biosimilars Market Size by Application
  6. 11.2.1 Asia Biosimilars Revenue by Application (2021-2032)
  7. 11.2.2 Asia Biosimilars Sales by Application (2021-2032)
  8. 11.2.3 Asia Biosimilars Price by Application (2021-2032)
  9. 11.3 Asia Biosimilars Market Size by Country
  10. 11.3.1 Asia Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Biosimilars Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Biosimilars Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Biosimilars Market Size by Type
  2. 12.1.1 SAMEA Biosimilars Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Biosimilars Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Biosimilars Price by Type (2021-2032)
  5. 12.2 SAMEA Biosimilars Market Size by Application
  6. 12.2.1 SAMEA Biosimilars Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Biosimilars Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Biosimilars Price by Application (2021-2032)
  9. 12.3 SAMEA Biosimilars Market Size by Country
  10. 12.3.1 SAMEA Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Biosimilars Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Biosimilars Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Biosimilars Value Chain Analysis
  2. 13.1.1 Biosimilars Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Biosimilars Production Mode & Process
  6. 13.2 Biosimilars Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Biosimilars Distributors
  9. 13.2.3 Biosimilars Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst